Body mass index in chronic heart failure: Association with biomarkers of neurohormonal activation, inflammation and endothelial dysfunction

BMC Cardiovascular Disorders

Volumn 13, Issue , 2013, Pages

  Christensen, Heidi M ^a   Schou, Morten ^b   Goetze, Jens P ^b,c   Faber, Jens ^a,b   Frystyk, Jan ^d,e   Flyvbjerg, Allan ^d,e   Kistorp, Caroline ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Rigshospitalet   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e AARHUS UNIVERSITY   (Denmark)

Author keywords

Biomarkers; Body mass index; Chronic heart failure

Indexed keywords

ADIPONECTIN; ALPHA DEFENSIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; COPEPTIN; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE TYPE A; PROADRENOMEDULLIN; UNCLASSIFIED DRUG; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; PEPTIDE HORMONE;

AGE; AGED; ARTICLE; BODY MASS; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; NEW YORK HEART ASSOCIATION CLASS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX; BLOOD; CHRONIC DISEASE; COHORT ANALYSIS; HEART STROKE VOLUME; INFLAMMATION; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BODY MASS INDEX; C-REACTIVE PROTEIN; CHRONIC DISEASE; COHORT STUDIES; CROSS-SECTIONAL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HEART FAILURE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NEUROTRANSMITTER AGENTS; PEPTIDE HORMONES; STROKE VOLUME;

EID: 84884800976     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/1471-2261-13-80     Document Type: Article

References (31)

1. Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997, 349:1050-1053. 10.1016/S0140-6736(96)07015-8, 9107242.
2. Oreopoulos A, Padwal R, Kalantar-Zadeh K, Fonarow GC, Norris CM, McAlister FA. Body mass index and mortality in heart failure: a meta-analysis. Am Heart J 2008, 156:13-22. 10.1016/j.ahj.2008.02.014, 18585492.
3. Bordicchia M, Liu D, Amri EZ, Ailhaud G, Dessi-Fulgheri P, Zhang C, et al. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest 2012, 122:1022-1036. 10.1172/JCI59701, 3287224, 22307324.
4. Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem 2006, 52:1528-1538. 10.1373/clinchem.2006.069575, 16777915.
5. Christensen HM, Kistorp C, Schou M, Keller N, Zerahn B, Frystyk J, et al. Prevalence of cachexia in chronic heart failure and characteristics of body composition and metabolic status. Endocrine 2012, 43:626-634.
6. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005, 112:1756-1762. 10.1161/CIRCULATIONAHA.104.530972, 16157772.
7. McEntegart MB, Awede B, Petrie MC, Sattar N, Dunn FG, MacFarlane NG, et al. Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur Heart J 2007, 28:829-835. 10.1093/eurheartj/ehm033, 17403719.
8. Daniels LB, Clopton P, Potocki M, Mueller C, McCord J, Richards M, et al. Influence of age, race, sex, and body mass index on interpretation of midregional pro atrial natriuretic peptide for the diagnosis of acute heart failure: results from the BACH multinational study. Eur J Heart Fail 2012, 14:22-31. 10.1093/eurjhf/hfr157, 22140234.
9. von Haehling S, Jankowska EA, Morgenthaler NG, Vassanelli C, Zanolla L, Rozentryt P, et al. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. J Am Coll Cardiol 2007, 50:1973-1980. 10.1016/j.jacc.2007.08.012, 17996563.
10. George J, Patal S, Wexler D, Sharabi Y, Peleg E, Kamari Y, et al. Circulating adiponectin concentrations in patients with congestive heart failure. Heart 2006, 92:1420-1424. 10.1136/hrt.2005.083345, 1861042, 16621874.
11. Turer AT, Khera A, Ayers CR, Turer CB, Grundy SM, Vega GL, et al. Adipose tissue mass and location affect circulating adiponectin levels. Diabetologia 2011, 54:2515-2524. 10.1007/s00125-011-2252-z, 21779869.
12. Araujo JP, Lourenco P, Rocha-Goncalves F, Ferreira A, Bettencourt P. Adiponectin is increased in cardiac cachexia irrespective of body mass index. Eur J Heart Fail 2009, 11:567-572. 10.1093/eurjhf/hfp046, 19359328.
13. von Haehling S, Filippatos GS, Papassotiriou J, Cicoira M, Jankowska EA, Doehner W, et al. Mid-regional pro-adrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail 2010, 12:484-491. 10.1093/eurjhf/hfq031, 20215339.
14. Vila G, Riedl M, Maier C, Struck J, Morgenthaler NG, Handisurya A, et al. Plasma MR-proADM correlates to BMI and decreases in relation to leptin after gastric bypass surgery. Obesity (Silver Spring) 2009, 17:1184-1188.
15. Morawiec B, Kawecki D. Copeptin: a new marker in cardiology. J Cardiovasc Med (Hagerstown ) 2013, 14:19-25.
16. McMurray JJ, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, et al. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation 2009, 120:2188-2196. 10.1161/CIRCULATIONAHA.109.849117, 19917888.
17. Rawson ES, Freedson PS, Osganian SK, Matthews CE, Reed G, Ockene IS. Body mass index, but not physical activity, is associated with C-reactive protein. Med Sci Sports Exerc 2003, 35:1160-1166. 10.1249/01.MSS.0000074565.79230.AB, 12840637.
18. Christensen HM, Frystyk J, Faber J, Schou M, Flyvbjerg A, Hildebrandt P, et al. alpha-Defensins and outcome in patients with chronic heart failure. Eur J Heart Fail 2012, 14:387-394. 10.1093/eurjhf/hfs021, 22357441.
19. Galatius S, Gustafsson F, Nielsen PH, Atar D, Hildebrandt PR. An integrated approach to diagnosis and therapeutic management of patients with systolic heart failure in the Copenhagen metropolitan area. Am Heart J 2002, 144:E2. 10.1067/mhj.2002.123841, 12177660.
20. Joseph G, Tarnow L, Astrup AS, Hansen TK, Parving HH, Flyvbjerg A, et al. Plasma alpha-defensin is associated with cardiovascular morbidity and mortality in type 1 diabetic patients. J Clin Endocrinol Metab 2008, 93:1470-1475. 10.1210/jc.2007-1910, 18211979.
21. Karl J, Borgya A, Gallusser A, Huber E, Krueger K, Rollinger W, et al. Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit. Scand J Clin Lab Invest Suppl 1999, 230:177-181.
22. Frystyk J, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A. Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia 2005, 48:1911-1918. 10.1007/s00125-005-1850-z, 16078018.
23. Morgenthaler NG, Struck J, Thomas B, Bergmann A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 2004, 50:234-236. 10.1373/clinchem.2003.021204, 14709661.
24. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem 2005, 51:1823-1829. 10.1373/clinchem.2005.051110, 16099941.
25. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006, 52:112-119. 10.1373/clinchem.2005.060038, 16269513.
26. Lafontan M, Moro C, Berlan M, Crampes F, Sengenes C, Galitzky J. Control of lipolysis by natriuretic peptides and cyclic GMP. Trends Endocrinol Metab 2008, 19:130-137. 10.1016/j.tem.2007.11.006, 18337116.
27. Masson S, Gori F, Latini R, Milani V, Flyvbjerg A, Frystyk J, et al. Adiponectin in chronic heart failure: influence of diabetes and genetic variants. Eur J Clin Invest 2011, 41:1330-1338. 10.1111/j.1365-2362.2011.02548.x, 21623778.
28. Bhandari SS, Davies JE, Struck J, Ng LL. Influence of confounding factors on plasma mid-regional pro-adrenomedullin and mid-regional pro-A-type natriuretic peptide concentrations in healthy individuals. Biomarkers 2011, 16:281-287. 10.3109/1354750X.2011.553750, 21438719.
29. Bartels ED, Nielsen JM, Bisgaard LS, Goetze JP, Nielsen LB. Decreased expression of natriuretic peptides associated with lipid accumulation in cardiac ventricle of obese mice1. Endocrinology 2010, 151:5218-5225. 10.1210/en.2010-0355, 20844006.
30. Birkenfeld AL, Boschmann M, Engeli S, Moro C, Arafat AM, Luft FC, et al. Atrial natriuretic peptide and adiponectin interactions in man 1. PLoS One 2012, 7:e43238. 10.1371/journal.pone.0043238, 3420865, 22916229.
31. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice 2. Proc Natl Acad Sci U S A 2001, 98:2005-2010. 10.1073/pnas.98.4.2005, 29372, 11172066.